Keywords: Seattle Genetics, Abbott Labs, ADC technology, Oncology target, Antibody-drug conjugate

Seattle Genetics in antibody-drug conjugate accord with Abbott

Article | 23 March 2011

Print This

In a third licensing deal this year, Seattle Genetics (Nasdaq: SGEN) says it has entered into a collaboration agreement with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in